Selvita expects revenue dynamics to be as good as in previous years

Selvita is optimistic about the level of revenues expected for the entire year 2022 and expects dynamics "as good as in previous years," the management board members informed.

In the first half of the year, the Selvita capital group generated operating revenues of PLN 199 million, compared to PLN 142 million a year earlier. In 2021, the company had revenues of PLN 317 million, compared to PLN 142 million a year earlier.

"We can see that we are on the way to show the dynamics as good as in previous years," said co-founder, significant shareholder and CEO of Selvita Bogusław Sieczkowski during a press conference.

“As far as the backlog is concerned, we have 32% more revenue - already recognized, or the one that we have in signed orders by the end of the year. The services provided in Poland are characterized by the greatest dynamics, ie 43%; for regulatory services this is 68% dynamics; very stable, solid growth in drug discovery services - an increase of 24%. This allows us to be optimistic about the achievements that we will present in March in a full year ”- added CFO Dariusz Kurdas.

Selvita shares (previously Selvita CRO S.A.) debuted in mid-October 2019 on the main market of the Warsaw Stock Exchange. Earlier, the registry court approved the division of Selvita. The court's decision meant for Selvita S.A. formal finalization of the procedure related to the division of the company into two independent entities - Selvita S.A. (formerly Selvita CRO S.A.) and Ryvu Therapeutics S.A. (formerly Selvita S.A.).

Our privacy policy